Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000374628

Medchemexpress LLC 6PPD-Q | 2754428-18-5 | C18H22N2O2 | 25 MG
SDP

Catalog No. 5000374628
Encompass_Preferred

6PPD-Q (6PPD-Quinone) is an environmental pollutant detected in human urine and widely present in the environment. It targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1, with CNR2 showing the highest binding affinity, potentially acting as a CNR2 receptor agonist to activate cannabinoid receptors. It can induce intestinal inflammation and barrier damage by disrupting mitochondrial function, reducing neuronal glycolysis metabolites and TCA cycle intermediates, and exacerbating α-synuclein (α-syn) aggregation. This compound is applicable for research in environmental toxicology, neurodegenerative diseases, and inflammation-related disorders.

  • Targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1
  • Acts as a CNR2 receptor agonist
  • Induces intestinal inflammation and barrier damage
  • Reduces neuronal glycolysis metabolites and TCA cycle intermediates
  • Exacerbates α-synuclein (α-syn) aggregation

Catalog No. 50-003-74628 Supplier Medchemexpress LLC Supplier No. 25MGHY153169
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

6PPD-Q (6PPD-Quinone) is an environmental pollutant detected in human urine and widely present in the environment. It targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1, with CNR2 showing the highest binding affinity, potentially acting as a CNR2 receptor agonist to activate cannabinoid receptors. It can induce intestinal inflammation and barrier damage by disrupting mitochondrial function, reducing neuronal glycolysis metabolites and TCA cycle intermediates, and exacerbating α-synuclein (α-syn) aggregation. This compound is applicable for research in environmental toxicology, neurodegenerative diseases, and inflammation-related disorders.

  • Targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1
  • Acts as a CNR2 receptor agonist
  • Induces intestinal inflammation and barrier damage
  • Reduces neuronal glycolysis metabolites and TCA cycle intermediates
  • Exacerbates α-synuclein (α-syn) aggregation

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.